During Covid-19 Pandemic
In January 2020, just before Chinese New Year, we noticed the novel coronavirus outbreak, Drawray’s parent company YHLO set up a special force team in R&D to develop SARS-CoV-2 IgG/IgM assays. With Frank Xia’s experiences in 2003 SARS IgG ELISA assay, YHLO finished R&D of SARS-CoV-2 IgG/IgM on Feb 10, 2020. What’s more, the company had donated more than 3 millions tests of GLINE-2019-nCoV Ag assays and over 1 million tests of SARS-CoV-2 IgG/IgM assays to all over the world.
Up to March 25th, 2022, the company has donated 1.2 million YHLO COVID-19 Rapid Antigen Tests to Hong Kong together with Hongkong partner. On March 25th, 2022, the company and 123 people from all walks of life in Hong Kong and the Mainland China jointly initiated the establishment of the "Hong Kong Anti-epidemic Alliance”.